GlaxoSmithKline [GLAXO] vs Senores [SENORES] Detailed Stock Comparison

GlaxoSmithKline

NSE
Loading...

Senores

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: GlaxoSmithKline wins in 12 metrics, Senores wins in 5 metrics, with 0 ties. GlaxoSmithKline appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricGlaxoSmithKlineSenoresBetter
P/E Ratio (TTM)47.3948.74GlaxoSmithKline
Price-to-Book Ratio23.094.26Senores
Debt-to-Equity Ratio0.5138.75GlaxoSmithKline
PEG Ratio3.81N/AN/A
EV/EBITDA36.2829.44Senores
Profit Margin (TTM)25.41%14.82%GlaxoSmithKline
Operating Margin (TTM)29.27%20.42%GlaxoSmithKline
EBITDA Margin (TTM)29.27%20.42%GlaxoSmithKline
Return on Equity47.54%7.21%GlaxoSmithKline
Return on Assets (TTM)22.58%4.77%GlaxoSmithKline
Free Cash Flow (TTM)$12.65B$-2.03BGlaxoSmithKline
Dividend Yield1.65%N/AN/A
1-Year Return-1.52%20.06%Senores
Price-to-Sales Ratio (TTM)12.057.23Senores
Enterprise Value$425.69B$30.24BGlaxoSmithKline
EV/Revenue Ratio11.386.63Senores
Gross Profit Margin (TTM)64.27%52.91%GlaxoSmithKline
Revenue per Share (TTM)$221$116GlaxoSmithKline
Earnings per Share (Diluted)$56.12$14.68GlaxoSmithKline
Beta (Stock Volatility)0.04N/AN/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

GlaxoSmithKline vs Senores Stock Performance Analysis

Loading Price Chart...

GlaxoSmithKline
Senores
GlaxoSmithKline Stock Overview | Senores Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
GlaxoSmithKline1.62%-1.79%-3.96%-19.57%-3.58%20.84%
Senores-0.56%-4.06%-1.93%18.10%22.01%20.44%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
GlaxoSmithKline-1.52%93.34%80.13%-18.74%17.61%513.98%
Senores20.06%20.06%20.06%20.06%20.06%20.06%

News Based Sentiment: GlaxoSmithKline vs Senores

GlaxoSmithKline

News based Sentiment: MIXED

September 2025 brought both positive earnings results and concerning signals for GSK Pharma. While profitability improved, the stock faced a decline and regulatory hurdles persist. The planned oncology launches offer potential, but the overall picture is complex, making it a mixed month for investors.

View GlaxoSmithKline News Sentiment Analysis

Senores

News based Sentiment: MIXED

September was a significant month for Senores Pharmaceuticals, featuring strong financial results, key strategic investments, and an acquisition. However, the stock experienced volatility and recent declines, creating a mixed investment picture. The company's focus on US expansion through SPI is a key theme.

View Senores News Sentiment Analysis

Performance & Financial Health Analysis: GlaxoSmithKline vs Senores

MetricGLAXOSENORES
Market Information
Market Cap i₹458.57B₹32.95B
Market Cap CategoryLarge capSmall cap
10 Day Avg. Volume i97,602305,178
90 Day Avg. Volume i94,903283,356
Last Close₹2,741.00₹688.10
52 Week Range₹1,921.00 - ₹3,515.70₹435.25 - ₹751.20
% from 52W High-22.04%-8.40%
All-Time High₹3,872.00 (Mar 28, 2016)₹751.20 (Sep 09, 2025)
% from All-Time High-29.21%-8.40%
Growth Metrics
Quarterly Revenue Growth-0.01%0.72%
Quarterly Earnings Growth0.12%0.84%
Financial Health
Profit Margin (TTM) i0.25%0.15%
Operating Margin (TTM) i0.29%0.20%
Return on Equity (TTM) i0.48%0.07%
Debt to Equity (MRQ) i0.5138.75
Cash & Liquidity
Book Value per Share (MRQ)₹115.19₹168.00
Cash per Share (MRQ)₹147.46₹89.88
Operating Cash Flow (TTM) i₹12.73B₹-71,800,000
Levered Free Cash Flow (TTM) i₹9.28B₹585.60M
Dividends
Last 12-Month Dividend Yield i1.65%N/A
Last 12-Month Dividend i₹54.00N/A

Valuation & Enterprise Metrics Analysis: GlaxoSmithKline vs Senores

MetricGLAXOSENORES
Price Ratios
P/E Ratio (TTM) i47.3948.74
Forward P/E i45.9422.36
PEG Ratio i3.81N/A
Price to Sales (TTM) i12.057.23
Price to Book (MRQ) i23.094.26
Market Capitalization
Market Capitalization i₹458.57B₹32.95B
Enterprise Value i₹425.69B₹30.24B
Enterprise Value Metrics
Enterprise to Revenue i11.386.63
Enterprise to EBITDA i36.2829.44
Risk & Other Metrics
Beta i0.04N/A
Book Value per Share (MRQ) i₹115.19₹168.00

Financial Statements Comparison: GlaxoSmithKline vs Senores

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)GLAXOSENORES
Revenue/Sales i₹8.05B₹1.30B
Cost of Goods Sold i₹2.88B₹613.60M
Gross Profit i₹5.17B₹689.40M
Research & Development iN/AN/A
Operating Income (EBIT) i₹2.36B₹281.80M
EBITDA i₹2.95B₹375.20M
Pre-Tax Income i₹2.79B₹264.90M
Income Tax i₹739.70M₹53.10M
Net Income (Profit) i₹2.05B₹211.80M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)GLAXOSENORES
Cash & Equivalents i₹5.39B₹1.05B
Total Current Assets i₹34.10B₹7.22B
Total Current Liabilities i₹19.05B₹2.41B
Long-Term Debt i₹24.92M₹1.71B
Total Shareholders Equity i₹19.51B₹8.12B
Retained Earnings i₹10.59B₹899.10M
Property, Plant & Equipment i₹2.70B₹64.00M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)GLAXOSENORES
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLAXOSENORES
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i97,602305,178
Average Daily Volume (90 Day) i94,903283,356
Shares Outstanding i169.41M46.05M
Float Shares i41.29M18.02M
% Held by Insiders i0.76%0.56%
% Held by Institutions i0.09%0.08%

Dividend Analysis & Yield Comparison: GlaxoSmithKline vs Senores

MetricGLAXOSENORES
Last 12-Month Dividend i₹54.00N/A
Last 12-Month Dividend Yield i1.65%N/A
3-Year Avg Annual Dividend i₹59.33N/A
3-Year Avg Dividend Yield i1.86%N/A
3-Year Total Dividends i₹178.00N/A
Ex-Dividend DateMay 30, 2025N/A